No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
HK Stock MarketDetailed Quotes
01877 JUNSHI BIO
- 11.980
- +0.240+2.04%
Trading Jun 17 15:12 CST
11.81BMarket Cap-5296P/E (TTM)
12.060High11.500Low531.40KVolume11.540Open11.740Pre Close6.28MTurnover0.24%Turnover RatioLossP/E (Static)985.69MShares25.80052wk High1.56P/B2.63BFloat Cap9.17052wk Low--Dividend TTM219.30MShs Float97.150Historical High--Dividend LFY4.77%Amplitude9.170Historical Low11.815Avg Price200Lot Size--Div YieldTTM--Div Yield LFY
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Shanghai Junshi Biosciences - Approval of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Es-Sclc by Nmpa
Junshi Biosciences (688180.SH): There are currently no COVID-19 vaccine products in the development pipeline.
Junshi Bio (688180.SH) stated on the investor interaction platform on June 12 that there is currently no vaccine product against COVID-19 in the company's research and development pipeline.
Junshi Bio (688180.SH): The new indication for the use of Toripalimab monotherapy in first-line treatment for extensive-stage small cell lung cancer has been approved for market application.
On June 12th, Gelunhui reported that Junshi Bio (688180.SH) has received a 'Pharmaceutical Registration Certificate' approved and issued by the National Medical Products Administration for Toripalimab (Commodity Name: Tuoyi, Product Code: JS001), which is used in combination with Icotinib and Platinum-based drugs for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) as a new indication. Due to the commercialization of medicine that can be affected by certain uncertainties after obtaining market approval.
Junshi Bio Achieves Primary Endpoints in Phase 3 Trial of Liver Cancer Treatment
Shanghai Junshi Biosciences (SHA:688180, HKG:1877) achieved the primary endpoints of a phase 3 trial for its toripalimab advanced liver cancer treatment, according to a Wednesday filing with the Shang
Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results
Shanghai Junshi Biosciences (HKG:1877) announced positive results from a Phase III clinical trial testing its drug toripalimab in combination with bevacizumab for advanced hepatocellular carcinoma (HC
Express News | Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined With Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
Comments
The company's weak revenue trend, unprofitability, and rapid decline in share price reflect poor fundamentals. Last year's performance indicates unresolved challenges, worse than the annualized loss of 9% over the last half decade.
Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83% 1
$Hang Seng Index(800000.HK$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
1
Despite Shanghai Junshi Biosciences' weak revenue growth, its P/S ratio aligns with industry peers, indicating investors may be overlooking limited growth expectations and paying a premium. However, this could risk investments as the weak revenue outlook may eventually impact share prices.
Shanghai Junshi Biosciences carries rising debt yet has surplus liquid assets, offsetting risk. Despite having net cash, being a loss-maker might impact its financial health. Be cautious of investing until positive cash flow is seen.
Key points:
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...
Read more
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg